|Sofinnova Partners|| |
The money is earmarked for three mid-stage studies of CT327 for psoriasis and dermatitis and CT200, which is being developed for Behcet's Disease.
|IRX Therapeutics |
|Existing investors|| |
The new money will be used to further develop IRX's cancer and viral disease product platform, including IRX-2 (citoplurikin), its lead candidate for cancer treatment.
|Inimex Pharmaceuticals |
|Morningside Venture Investments|| |
The company is launching the first clinical trials of an Innate Defense Regulator (IDR) drug in patients and assessing IDR drugs in a range of disease models.
Creabilis rounds up $30M